Myth Replacement Therapy: MPs Debate the Science of Mitochondria
By Dr. Ted Morrow,
BioNews
| 09. 08. 2014
The regulatory path to clinical trials of mitochondrial replacement therapy (MRT) was recently debated in the House of Commons. MRT is under development in the UK as way of potentially eliminating mitochondrial disease. The techniques essentially swap diseased mitochondria in the unfertilised or fertilised eggs of affected women for putatively healthy ones obtained from a donor. The outcome is unknown and evidence from animals suggest mismatching may occur between the nuclear DNA from the mother and the mitochondrial DNA (mtDNA) derived from the donor (1). The debate was called by a group of backbenchers that are unhappy about the pace with which the Government is apparently moving towards changing the regulations. The split in views in the chamber was fairly even.
Read more...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...